drugset
drugset / Trial / NCT03434197

Safety and Efficacy of SFPP in Knee Osteoarthritis

NCT03434197 ↗

Phase 3 Completed 313 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objectives of this study are to demonstrate the non-inferiority of esflurbiprofen plaster (SFPP) 40 mg applied for 2 weeks to diclofenac gel, the comparator, in terms of efficacy in patients with knee osteoarthritis (OA) and to examine the safety of SFPP.

Timeline

Start
2018-02-05
Primary completion
2021-01-11
Completion
2021-01-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac diethylamine Unknown 11.6 mg Topical
Subject Esflurbiprofen Small molecule 40 mg Topical

Indications

osteoarthritis, knee